Difference in serotonergic and noradrenergic regulation of human social behaviours.

Tse WS, Bond AJ.

Section of Clinical Psychopharmacology, 
Division of Psychological Medicine, 
Institute of Psychiatry, 
ASB, King's College London, SE5 8AF, UK. 
spklwst@iop.kcl.ac.uk
Psychopharmacology (Berl) 2002 Jan;159(2):216-21

ABSTRACT

RATIONALE: Treatment with antidepressants has been shown to affect social functioning, but drugs with actions on different neurotransmitters may have a different profile of effects. 

OBJECTIVE: To study the effects of acute manipulation of two neurotransmitters, serotonin and noradrenaline, on social behaviour in healthy volunteers. 

METHODS: Sixty volunteers were randomly assigned to a single dose of a selective noradrenaline reuptake inhibitor, reboxetine (4 mg), a selective serotonin reuptake inhibitor, citalopram (10 mg), or placebo. They socially interacted with a confederate behaving in a non-sociable manner in a stranger-dyadic social interaction paradigm 1.5 h postdrug.  Social behaviour during the interaction was video recorded by a hidden camera and subsequently analysed.  After the interaction, volunteers played the mixed-motive game with the confederate.  This game has been shown to measure cooperative behaviour and communication.  Volunteers read a short story and rated their mood predrug and before and after the interaction. 

RESULTS: Subjects on reboxetine showed reduced hand fiddling during the interaction and gave significantly more cooperative communications during the mixed-motive game.  More volunteers on reboxetine were classified as cooperative players.  On the reading task, the speech of subjects on citalopram showed less reduction of energy variation after the social interaction. 

CONCLUSION: Reboxetine had clear effects on social behaviour.  Noradrenaline was related to increased social engagement and cooperation and a reduction in self-focus. Citalopram had less effect on cooperative behaviour but serotonin may be associated with protection of the self from the negative consequences of social interaction.

Tianeptine | Moclobemide  Deprenyl  Picamilon | diabetes
     Home | Order
   www.AlzheimersTreatments.com
 

          Reboxetine  research / abstracts

  1.  Reboxetine  role in antidepressant therapy
  2.  Reboxetine  efficacy and tolerability
  3.  Reboxetine  clinical pharmacologic profile
  4.  Reboxetine  Inhibiting noradrenaline and serotonin reuptake 
  5.  Reboxetine  and depression in the elderly
  6.  Reboxetine  with severe major depressive disorder
  7.  Reboxetine  clinical efficacy in major depression
  8.  Reboxetine  tolerability and safety for major depression
  9.  Reboxetine  comparison with fluoxetine
 10. Reboxetine  versus fluoxetine, impact on social functioning
 11. Reboxetine  versus fluoxetine, differential effects
 12. Reboxetine  prevents relapse in  major depression
 13. Rebox
etine  efficacy compared with imipramine
 14. Noradrenaline reuptake inhibition
 15. Antidepressants  noradrenergic versus serotonergic
 16. Reb
oxetine  in the treatment of bulimia
 17. Reboxetine  hemodynamic effects in healthy males
 18. Reboxetine  effects of antidepressant therapy
 19. Reboxetine  place in antidepressant therapy
 20. Reboxetine  stimulant effects in patients with narcolepsy
 21. Reboxetine  selective noradrenaline reuptake inhibitor (NARI)

       Reboxetine  manufacturer's product insert

 

Hit Counter